KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Net Income (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Net Income for 8 consecutive years, with $62.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 400.34% year-over-year to $62.6 million, compared with a TTM value of -$24.3 million through Dec 2025, down 401.77%, and an annual FY2025 reading of -$22.7 million, up 56.17% over the prior year.
  • Net Income was $62.6 million for Q4 2025 at Esperion Therapeutics, up from -$32.0 million in the prior quarter.
  • Across five years, Net Income topped out at $62.6 million in Q4 2025 and bottomed at -$90.9 million in Q1 2021.
  • Average Net Income over 5 years is -$37.7 million, with a median of -$47.6 million recorded in 2021.
  • Peak annual rise in Net Income hit 400.34% in 2025, while the deepest fall reached 171.3% in 2025.
  • Year by year, Net Income stood at -$69.1 million in 2021, then rose by 17.69% to -$56.8 million in 2022, then decreased by 1.02% to -$57.4 million in 2023, then skyrocketed by 63.71% to -$20.8 million in 2024, then surged by 400.34% to $62.6 million in 2025.
  • Business Quant data shows Net Income for ESPR at $62.6 million in Q4 2025, -$32.0 million in Q3 2025, and -$13.4 million in Q2 2025.